Abstract
Synthetic small interfering RNAs (siRNAs) open promising new therapeutic perspectives in acute and chronic pathologies. A number of experiments in mice demonstrated the ability of naked siRNAs injected under a normal pressure to trigger gene silencing in vivo, translating into a measurable phenotype. We focus in this review on the information that we can gain from these experiments, and discuss how the specificity of the gene silencing in vivo can be controlled. Because the activity of most drugs increases with the dosing, we are prone to consider that increasing the concentration of siRNAs within cells enhances the efficiency and the duration of the silencing. However, because RNAi is a saturable process, and because increasing the siRNA concentration into cells can induce undesirable side effects, this must be demonstrated. We compare in this review the methods used to quantify and study the biodistribution of siRNAs in living animals, and discuss how these methods can help in designing for each model and each siRNA the most adequate protocol to silence a cognate target gene in vivo.
Current Topics in Medicinal Chemistry
Title: Systemic Delivery and Quantification of Unformulated Interfering RNAs In Vivo
Volume: 9 Issue: 12
Author(s): Aurelie Morin, Catherine Gallou-Kabani, Jacques R.R. Mathieu and Florence Cabon
Affiliation:
Abstract: Synthetic small interfering RNAs (siRNAs) open promising new therapeutic perspectives in acute and chronic pathologies. A number of experiments in mice demonstrated the ability of naked siRNAs injected under a normal pressure to trigger gene silencing in vivo, translating into a measurable phenotype. We focus in this review on the information that we can gain from these experiments, and discuss how the specificity of the gene silencing in vivo can be controlled. Because the activity of most drugs increases with the dosing, we are prone to consider that increasing the concentration of siRNAs within cells enhances the efficiency and the duration of the silencing. However, because RNAi is a saturable process, and because increasing the siRNA concentration into cells can induce undesirable side effects, this must be demonstrated. We compare in this review the methods used to quantify and study the biodistribution of siRNAs in living animals, and discuss how these methods can help in designing for each model and each siRNA the most adequate protocol to silence a cognate target gene in vivo.
Export Options
About this article
Cite this article as:
Morin Aurelie, Gallou-Kabani Catherine, Mathieu R.R. Jacques and Cabon Florence, Systemic Delivery and Quantification of Unformulated Interfering RNAs In Vivo, Current Topics in Medicinal Chemistry 2009; 9 (12) . https://dx.doi.org/10.2174/156802609789630820
DOI https://dx.doi.org/10.2174/156802609789630820 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Drug Therapy for Prostate Cancer: An Overview
Current Medicinal Chemistry - Anti-Cancer Agents Design and Development of Molecular Imaging Probes
Current Topics in Medicinal Chemistry Molecular Delivery of Plasmids for Genetic Vaccination
Current Pharmaceutical Biotechnology Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry Lafora Progressive Myoclonus Epilepsy: Recent Insights into Cell Degeneration
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Kisspeptin: A Critical Regulator of Puberty and Reproductive Function
Current Drug Targets Nucleic Acids as Therapeutic Agents
Current Topics in Medicinal Chemistry Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Genesis of Dihydropyrimidinone Calcium Channel Blockers: Recent Progress in Structure-Activity Relationships and Other Effects
Mini-Reviews in Medicinal Chemistry Current Perspectives in Prostate Cancer Vaccines
Anti-Cancer Agents in Medicinal Chemistry What is the Current Role of Immunotherapy for Colon Cancer?
Reviews on Recent Clinical Trials Intracellular Calcium, Endothelial Cells and Angiogenesis
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in Polymeric Nanosystems for Treating Cutaneous Melanoma and Its Metastasis
Current Pharmaceutical Design miR-135a Suppresses Calcification in Senescent VSMCs by Regulating KLF4/STAT3 Pathway
Current Vascular Pharmacology Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions
Drug Metabolism Letters Zinc Homeostasis-regulating Proteins: New Drug Targets for Triggering Cell Fate
Current Drug Targets Statins and Cancer
Anti-Cancer Agents in Medicinal Chemistry Bone Seeking Radiopharmaceuticals for Palliation of Pain in Cancer Patients with Osseous Metastases
Anti-Cancer Agents in Medicinal Chemistry Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacology and Therapeutic Applications of Enediyne Antitumor Antibiotics
Current Molecular Pharmacology